CD169+ macrophages regulate PD-L1 expression via type I interferon and thereby prevent severe immunopathology after LCMV infection

被引:0
|
作者
Namir Shaabani
Vikas Duhan
Vishal Khairnar
Asmae Gassa
Rita Ferrer-Tur
Dieter Häussinger
Mike Recher
Gennadiy Zelinskyy
Jia Liu
Ulf Dittmer
Mirko Trilling
Stefanie Scheu
Cornelia Hardt
Philipp A Lang
Nadine Honke
Karl S Lang
机构
[1] Institute of Immunology,Department of Gastroenterology
[2] University Hospital Essen,Department of Immunology and Microbial Science
[3] University of Duisburg-Essen,Department of Biomedicine
[4] Hepatology and Infectious Diseases,Department of Infectious Disease
[5] Heinrich-Heine-University Düsseldorf,undefined
[6] The Scripps Research Institute,undefined
[7] Clinic for Primary Immunodeficiency,undefined
[8] Medical Outpatient Unit and Immunodeficiency Laboratory,undefined
[9] University Hospital,undefined
[10] Institute of Virology,undefined
[11] University Hospital Essen,undefined
[12] University of Duisburg-Essen,undefined
[13] Union Hospital,undefined
[14] Tongji Medical College,undefined
[15] Huazhong University of Science and Technology,undefined
[16] Institute of Medical Microbiology and Hospital Hygiene,undefined
[17] Heinrich-Heine-University Düsseldorf,undefined
来源
Cell Death & Disease | 2016年 / 7卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Upon infection with persistence-prone virus, type I interferon (IFN-I) mediates antiviral activity and also upregulates the expression of programmed death ligand 1 (PD-L1), and this upregulation can lead to CD8+ T-cell exhaustion. How these very diverse functions are regulated remains unknown. This study, using the lymphocytic choriomeningitis virus, showed that a subset of CD169+ macrophages in murine spleen and lymph nodes produced high amounts of IFN-I upon infection. Absence of CD169+ macrophages led to insufficient production of IFN-I, lower antiviral activity and persistence of virus. Lack of CD169+ macrophages also limited the IFN-I-dependent expression of PD-L1. Enhanced viral replication in the absence of PD-L1 led to persistence of virus and prevented CD8+ T-cell exhaustion. As a consequence, mice exhibited severe immunopathology and died quickly after infection. Therefore, CD169+ macrophages are important contributors to the IFN-I response and thereby influence antiviral activity, CD8+ T-cell exhaustion and immunopathology.
引用
收藏
页码:e2446 / e2446
相关论文
共 21 条
  • [1] CD169+ macrophages regulate PD-L1 expression via type I interferon and thereby prevent severe immunopathology after LCMV infection
    Shaabani, Namir
    Duhan, Vikas
    Khairnar, Vishal
    Gassa, Asmae
    Ferrer-Tur, Rita
    Haeussinger, Dieter
    Recher, Mike
    Zelinskyy, Gennadiy
    Liu, Jia
    Dittmer, Ulf
    Trilling, Mirko
    Scheu, Stefanie
    Hardt, Cornelia
    Lang, Philipp A.
    Honke, Nadine
    Lang, Karl S.
    CELL DEATH & DISEASE, 2016, 7 : e2446 - e2446
  • [2] CD8+ T Cells Mediate Lethal Lung Pathology in the Absence of PD-L1 and Type I Interferon Signalling following LCMV Infection
    Spiteri, Alanna G.
    Suprunenko, Tamara
    Cutts, Erin
    Suen, Andrew
    Ashhurst, Thomas M.
    Viengkhou, Barney
    King, Nicholas J. C.
    Hofer, Markus J.
    VIRUSES-BASEL, 2024, 16 (03):
  • [3] Breast cancer cells promote CD169+ macrophage-associated immunosuppression through JAK2-mediated PD-L1 upregulation on macrophages
    Jing, Weiqiang
    Guo, Xing
    Wang, Ganyu
    Bi, Yuxuan
    Han, Lihui
    Zhu, Qingfen
    Qiu, Chunhong
    Tanaka, Masato
    Zhao, Yunxue
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 78
  • [4] A functional interaction between plasmacytoid dendritic cells (pDCs) and CD169+ macrophages in the bone marrow regulates pDCs production of type I interferon during severe malaria
    Moore, Jamie M.
    Fooksman, David R.
    Lauvau, Gregoire
    JOURNAL OF IMMUNOLOGY, 2020, 204 (01):
  • [5] Usp22 Deficiency Leads to Downregulation of PD-L1 and Pathological Activation of CD8+ T Cells and Causes Immunopathology in Response to Acute LCMV Infection
    Friebus-Kardash, Justa
    Christ, Theresa Charlotte
    Dietlein, Nikolaus
    Elwy, Abdelrahman
    Abdelrahman, Hossam
    Holnsteiner, Lisa
    Hu, Zhongwen
    Rodewald, Hans-Reimer
    Lang, Karl Sebastian
    VACCINES, 2023, 11 (10)
  • [6] PD-L1 expression and type-I interferon response in non-small cell lung cancer
    Thomsen, C.
    Meristoudis, C.
    VIRCHOWS ARCHIV, 2024, 485 : S452 - S452
  • [7] PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I IFN pathway
    Hodgins, Jonathan J.
    Abou-Hamad, John
    O'Dwyer, Colin Edward
    Hagerman, Ash
    Yakubovich, Edward
    Tanese de Souza, Christiano
    Marotel, Marie
    Buchler, Ariel
    Fadel, Saleh
    Park, Maria M.
    Fong-McMaster, Claire
    Crupi, Mathieu F.
    Makinson, Olivia Joan
    Kurdieh, Reem
    Rezaei, Reza
    Dhillon, Harkirat Singh
    Ilkow, Carolina S.
    Bell, John C.
    Harper, Mary-Ellen
    Rotstein, Benjamin H.
    Auer, Rebecca C.
    Vanderhyden, Barbara C.
    Sabourin, Luc A.
    Bourgeois-Daigneault, Marie-Claude
    Cook, David P.
    Ardolino, Michele
    JOURNAL OF EXPERIMENTAL MEDICINE, 2024, 221 (07):
  • [8] Mitogen-activated protein kinase phosphatase-1 controls PD-L1 expression by regulating type I interferon during systemic Escherichia coli infection
    Barley, Timothy J.
    Murphy, Parker R.
    Wang, Xiantao
    Bowman, Bridget A.
    Mormol, Justin M.
    Mager, Carli E.
    Kirk, Sean G.
    Cash, Charles J.
    Linn, Sarah C.
    Meng, Xiaomei
    Nelin, Leif D.
    Chen, Bernadette
    Hafner, Markus
    Zhang, Jian
    Liu, Yusen
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2022, 298 (05)
  • [9] TYPE I INTERFERON-INDUCED PD-L1 AND IL-10 SUPPRESS TH1 PRIMING DURING PERSISTENT VIRAL INFECTION
    Snell, L. M.
    Osokine, I.
    Yamada, D. H.
    Elsaesser, H. J.
    Brooks, D. G.
    CYTOKINE, 2016, 87 : 82 - 82
  • [10] PD-L1 Expression is Predominant in CD68+Tumor-Associated Macrophages in Stage I-III Non-Small Cell Lung Cancers
    Sepesi, B.
    Federico, L.
    Mitchell, K.
    Parra, E.
    Cruz, A. Francisco
    Ravelli, A.
    Haymaker, C.
    Karpinets, T.
    Cascone, T.
    Weissferdt, A.
    Antonoff, M. B.
    Walsh, G.
    Bernatchez, C.
    Roth, J.
    Zhang, J.
    Roarty, E.
    Landry, L. C. A. D. L.
    Vaporciyan, A.
    Swisher, S.
    Heymach, J.
    Wistuba, I.
    Gibbons, D.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S516 - S516